In short
This article discusses a clinical trial investigating the use of a drug combination called APPA, which contains paeonol and apocynin, for treating knee osteoarthritis. The study aims to assess the effectiveness, safety, and tolerability of APPA in reducing pain and improving symptoms, physical functioning, and quality of life in adults with knee osteoarthritis. This placebo-controlled, double-blinded, randomized trial will help determine the optimal dosage for potential future treatments.
At a glance
- Study Type
- Phase II, placebo-controlled, double-blinded, randomized, dose-finding trial
- Drug
- APPA (combination of apocynin and paeonol)
- Condition
- Knee osteoarthritis
- Primary Objective
- Evaluate change in pain of the target knee
- Secondary Objectives
- Evaluate safety, tolerability, changes in OA symptoms, physical functioning, and quality of life
- Key Inclusion Criteria
- Age 40-85, femorotibial osteoarthritis, specific pain and radiological criteria
- Key Exclusion Criteria
- Hypersensitivity to APPA, current malignancy, BMI ≥ 40 kg/m2, certain medication use
- Primary Endpoint
- Change from baseline in WOMAC pain sub-score at week 12
- Key Secondary Endpoints
- Changes in WOMAC total score, ICOAP scores, quality of life, adverse events
- Maximum Daily Dose
- 2400 mg
- Treatment Duration
- 84 days (12 weeks)
What is PAEONOL?
PAEONOL is an investigational drug being studied for the treatment of knee osteoarthritis. It is part of a combination medication called APPA, which consists of two active substances: paeonol and apocynin. This medication is being developed as a potential new therapy for people suffering from knee osteoarthritis pain.
Medical Condition: Knee Osteoarthritis
Knee osteoarthritis is a common form of arthritis that affects the knee joint. It occurs when the protective cartilage that cushions the ends of the bones in the knee wears down over time. This condition can cause pain, stiffness, and reduced mobility in the affected knee.
Clinical Trial Information
A clinical trial is currently underway to evaluate the effectiveness and safety of APPA (the combination of paeonol and apocynin) for treating knee osteoarthritis. This trial is known as a phase II study, which means it aims to gather more information about the drug's effectiveness and safety in a larger group of patients.
The study is described as a "placebo-controlled, double-blinded, randomized, dose-finding trial." Let's break down what this means:
- Placebo-controlled: Some participants will receive a placebo (a substance with no active ingredients) instead of the actual drug. This helps researchers determine if the drug's effects are genuinely due to the medication itself.
- Double-blinded: Neither the participants nor the researchers directly involved in the study know who is receiving the actual drug and who is receiving the placebo. This helps prevent bias in the study results.
- Randomized: Participants are randomly assigned to either the treatment group (receiving APPA) or the placebo group.
- Dose-finding: The study aims to determine the most effective and safe dose of the medication.
How PAEONOL Works
While the exact mechanism of action is not fully described in the provided information, PAEONOL is being studied as part of the APPA combination for its potential to relieve pain and improve symptoms associated with knee osteoarthritis. The combination of paeonol and apocynin may have anti-inflammatory and pain-relieving properties that could benefit patients with this condition.
Eligibility Criteria for the Study
To participate in this clinical trial, patients must meet certain criteria. Some key inclusion criteria include:
- Age between 40 and 85 years
- Diagnosed with femorotibial osteoarthritis of the knee
- Specific level of knee pain as measured by a standardized scale (WOMAC pain sub-score)
- Previous failure or intolerance to at least one other osteoarthritis therapy
There are also several exclusion criteria, such as certain medical conditions, recent surgeries, or use of specific medications that would prevent participation in the study.
Study Objectives
The main goal of this clinical trial is to evaluate how APPA affects pain in the target knee. Additionally, the study aims to assess:
- Safety and tolerability of APPA
- Changes in overall osteoarthritis symptoms
- Improvements in physical functioning
- Changes in quality of life for patients taking the medication
Potential Benefits of PAEONOL
If proven effective, PAEONOL (as part of the APPA combination) could offer several potential benefits for patients with knee osteoarthritis:
- Reduced knee pain
- Improved physical function and mobility
- Better quality of life
- A new treatment option for those who haven't responded well to other therapies
Safety Considerations
As with any investigational drug, safety is a crucial aspect of the study. The researchers will be closely monitoring participants for any side effects or adverse reactions. Some safety measures in the study include:
- Regular monitoring of vital signs, laboratory tests, and electrocardiogram (ECG) parameters
- Tracking the nature, incidence, and severity of any adverse events
- Excluding participants with certain medical conditions or those taking medications that could interact with the study drug
It's important to note that as an investigational drug, the full safety profile of PAEONOL is not yet known, and more research is needed to fully understand its potential risks and benefits.